HEALIOS K.K.

Research HEALIOS K.K. (6VX) on Bullrun: market cap EUR 179.55M, P/E 133.0. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 179.55M; P/E is 133.0.

Peer valuation comparison

Latest P/E is 133x versus a Healthcare sector median of 24.46x (443.7% above).

Latest P/E is 133x versus a Japan median of 16.54x (704.1% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025JPY 104.00M-JPY 2.22B-JPY 3.33B-109.6%n/aJPY 5.68BJPY 2.61BJPY 4.89B
FY2024JPY 560.00M-JPY 4.24B-JPY 2.12B77.1%-47.86JPY 3.67BJPY 2.66BJPY 2.06B
FY2023JPY 121.00M-JPY 3.82B-JPY 2.85B90.1%-56.22JPY 6.72BJPY 4.53BJPY 3.86B
FY2022JPY 90.00M-JPY 5.17B-JPY 4.86B100.0%-90.67JPY 7.25BJPY 7.15BJPY 4.38B
FY2021n/an/an/an/a-99.51n/an/an/a

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-24EUR 179.55M133.0n/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 EUR.

About HEALIOS K.K.

Healios K.K., together with its subsidiaries, engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051, which is preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is preparing for phase 3 clinical trial for the treatment of ischemic stroke;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is HEALIOS K.K.'s market cap?

HEALIOS K.K.'s market capitalization is EUR 179.55M.

What is HEALIOS K.K.'s P/E ratio?

HEALIOS K.K.'s price-to-earnings (P/E) ratio is 133.0.

What does HEALIOS K.K. do?

Healios K.K., together with its subsidiaries, engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States.